TCRT news

Alaunos Therapeutics, Inc. filed its Second Amended and Restated By-laws, amending and restating the version adopted in January 2026. The update includes new definitions and governance rules.

Alaunos Therapeutics reported new preclinical data showing ALN1003 treatment resulted in lower liver weight after adjusting for body fat percentage in a 48-day diet-induced obesity study. This finding supports the efficacy hypothesis of ALN1003 and aligns with previous results showing reduced liver …

Alaunos Therapeutics reported preclinical data showing its ALN1003 candidate demonstrated consistent improvements across multiple metabolic markers including body weight, insulin sensitivity, and liver health in diet-induced obese mice. The positive early-stage results support continued development …